By Sarah N. Lynch WASHINGTON (Reuters) – Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing, the company disclosed. The company, which is headquartered in Israel, said late on Friday it received subpoenas on Thursday from the U.S. Justice Department’s Antitrust Division. The subpoenas seek documents related to “corporate and employee records, generic pharmaceutical products and pricing” and the company’s “communications with competitors and others” related to the sale of generic products.
Continued here:
U.S. Justice Department subpoenas Taro over generic drug pricing
